Home
Resources
Follow portfolio news
...

Biopharmaceuticals: WuXi Biologics now manages 817 projects

Published on
12/2/2025
Amended on
6/11/2026
0
minute(s)
Odyssey 2021
Wuxi Biologics
In 2024, Wuxi Biologics added 151 new projects to its portfolio, reaching a total of 817 active projects. Our CRDMO (Contract Research, Development and Manufacturing) model enables us to support our customers at every stage of new drug development.
By
Charles Pinsolle
Charles Pinsolle
Biopharmaceuticals: WuXi Biologics now manages 817 projects
This article has been automatically translated. Please excuse any inaccuracies or translation errors.
Dieser Artikel wurde automatisch übersetzt. Bitte entschuldigen Sie etwaige Ungenauigkeiten oder Übersetzungsfehler.
This article has been automatically translated. We apologize per inaccuracies or translation errors.

Growth driven by customer confidence

WuXi Biologics, a company featured in theOdyssey Vintage Altaroc Odyssey , employs two key strategies: “Follow the Molecule,” which involves supporting a drug throughout its development, and “Win the Molecule,” which aims to secure advanced and commercial projects. Thanks to these approaches, the company is experiencing rapid growth, with more than 50% of its new projects coming from the United States.

In 2024, the company also strengthened its manufacturing capabilities, notably with the use of single-use bioreactors, which improve drug production and reduce costs.

Reinforced global manufacturing

WuXi Biologics is expanding its production network in Europe and the United States. Its new site in Worcester, USA, is designed as a factory of the future, with state-of-the-art automated equipment. With its extensive production capacity and 99% batch success rate, the company is establishing itself as a key player in the sector.

A strong commitment to the environment

WuXi Biologics is also committed to sustainability. The company has received several awards for its environmental efforts and has been recognized by the United Nations for its solutions reducing the carbon footprint of biopharmaceutical players by 80%.

With solid growth and a strategy focused on innovation and ecology, WuXi Biologics continues to expand and strengthen its role in the biologics industry.

Other content in this topic

Explore our content collections, which bring together different formats around a single subject/issue/theme.
Follow portfolio news
News from the Vintage Altaroc Companies
Every two weeks, check out the latest announcements from the Vintage Altaroc companies.
Article
|
18
2026-11-18
Follow portfolio news
News from the Vintage Altaroc Companies
Every two weeks, check out the latest announcements from the Vintage Altaroc companies.
Article
|
04
2026-11-04
News from the Vintage Altaroc Companies
Follow portfolio news
News from the Vintage Altaroc Companies
Every two weeks, check out the latest announcements from the Vintage Altaroc companies.
Article
|
22
2026-10-22
From elite sports to medical AI: what's new in the portfolio Altaroc
Follow portfolio news
From elite sports to medical AI: what's new in the portfolio Altaroc
Software adopted by every NFL team, AI agents that have already conducted 180 million interactions with patients, and a platform used by nearly one in five Fortune 500 companies. A look at nine acquisitions by the " Vintage "Odyssey over the past three months.
Article
|
19
2026-10-19
Follow portfolio news
News from the Vintage Altaroc Companies
Every two weeks, check out the latest announcements from the Vintage Altaroc companies.
Article
|
08
2026-10-08
Interview with Raul Villar, CEO of Optro
Follow portfolio news
Interview with Raul Villar, CEO of Optro
Raul Villar Jr. unveils his platform's global growth strategy, powered by AI, and his partnership with Hg
Video
|
13
2026-08-13
Interview with Chris Maclin, CEO of Empyrean
Follow portfolio news
Interview with Chris Maclin, CEO of Empyrean
In Boston, Chris Maclin, CEO of Empyrean, explains how his technology platform protects banks and modernizes risk management
Video
|
29
2026-05-29
Interview with Ian Drysdale, CEO of One Inc.
Follow portfolio news
Interview with Ian Drysdale, CEO of One Inc.
Learn about the career of Ian Drysdale, CEO of One Inc, a specialist in payment infrastructure for the insurance industry.
Video
|
09
2026-04-09
Interview with Daniel Baker, CEO of Healthdrive
Follow portfolio news
Interview with Daniel Baker, CEO of Healthdrive
In Boston, Daniel Baker, CEO of HealthDrive, shares his vision for sustainable growth with a human impact.
Video
|
29
2026-01-29
Interview Jeff Wessler - CEO Heartbeat
Follow portfolio news
Interview Jeff Wessler - CEO Heartbeat
Dr. Jeff Wessler, founder of Heartbeat Health, pioneer of virtual-first cardiology in the United States
Video
|
25
2025-11-25
Special report - Focus on the United States: 10 hypergrowth companies
Follow portfolio news
Special report - Focus on the United States: 10 hypergrowth companies
As the historic driving force behind global private equity, the United States is home to some of the most dynamic companies on the planet. This report highlights 10 hyper-growth American companies, backed by private equity, at the heart of key economic sectors.
File
|
12
2024-03-12
No articles in this category yet.
Welcome to Altaroc
In accordance with applicable regulations, we ask that you complete your profile. This step is required to access the content and services offered on our websites.
Please fill out your profile to access the site
country of tax residence
Select
choosenCountry
Preferred language
Select
choosenLang
YOUR INVESTOR PROFILE
Financial intermediary or professional investor
Financial advisors, wealth managers, private bankers, or any other investment service providers.
Qualified Investor or Altaroc Investor
Experienced investor or Altaroc investor
Private investors who have already invested with Altaroc or who have a minimum investment capacity of €100,000.
Private investors who have previously invested in Altaroc who have a minimum investment capacity of 200,000 euros.
Non-professional (retail) investor
Individual investors with an investment capacity below €100,000.
Retail investors with an investment capacity of less than 200,000 euros.
Institutional investor
Pension funds, retirement schemes, asset management companies, and single-family offices.
Select your language and investor profile to continue
Select your investor profile to continue
Scroll down to accept General Terms and Conditions
The webpage you are trying to access is not available in your country.